Target intelligence / Profile preview

Large ribosomal subunit protein L27 (RPL27)

Target
RPL27
Molecular classification
Ribosomal protein, Structural constituent of ribosome, Component of large (60S) ribosomal subunit
01

Overview

Large ribosomal subunit protein L27 (RPL27) is a structural protein of the 60S ribosomal subunit, encoded by the RPL27 gene. It plays a key role in ribosome assembly, rRNA processing, and protein synthesis, with critical functions in cell proliferation and survival. Beyond its canonical role, RPL27 is implicated in human disease: mutations lead to Diamond-Blackfan anemia, while overexpression supports proliferation and stemness of cancer cells in colorectal and liver cancer. While not currently targeted by approved drugs, RPL27's essential role in translation and emerging data on its extra-ribosomal functions make it a candidate for future therapeutic targeting in cancer and hematologic disorders

Other names
60S ribosomal protein L27Ribosomal protein L27eL27DBA16L27Large ribosomal subunit protein eL27
02

Mechanism of action

Experimental: - Downregulation or knockdown suppresses cell proliferation and induces apoptosis in cancer models (mechanisms involve downregulation of cell cycle proteins like PLK1 and increased pro-apoptotic markers like Bax and Caspase-3, decreased Bcl-2). - Therapeutic targeting would likely aim to inhibit its function to suppress cancer cell viability and stemness.

03

Biological functions

Protein synthesis (translation)rRNA processingCell cycle regulationCell proliferationApoptosis (anti-apoptotic/pro-apoptotic regulation in cancer cells)
04

Disease associations

Diamond-Blackfan anemiaCancer (colorectal cancer, hepatocellular carcinoma)Bone marrow failure syndromes
05

Safety considerations

Potential for hematopoietic toxicity, as loss-of-function mutations cause Diamond-Blackfan anemia (congenital bone marrow failure)Targeting RPL27 may affect global protein synthesis, raising the risk for on-target toxicity and impact on normal rapidly-dividing cells.
06

Interacting drugs

No direct approved drugs are known to target RPL27 for clinical therapy; however, small molecules and chemical perturbations affecting RPL27 expression have been noted in chemical genomics datasets, and its potential as a therapeutic target in cancer is under investigation
07

Biomarkers

Mutations or expression levels of RPL27 are under investigation as biomarkers for: Diamond-Blackfan anemia diagnosisColorectal and hepatocellular carcinoma prognosis or progression

Beyond the preview

Go deeper on Large ribosomal subunit protein L27 (RPL27).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Large ribosomal subunit protein L27 (RPL27).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call